BioSpace News Archive

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2021.

Windtree Therapeutics, Inc., a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, reported financial results for the second quarter ended June 30, 2021 and provided key business updates.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its second quarter ended June 30, 2021.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2021 and provided a midyear corporate update.

Assertio Holdings, Inc., a leading commercial pharmaceutical company bringing differentiated products to patients, reported financial results for the second quarter ended June 30, 2021.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, reported second quarter 2021 financial results and operational progress.

ResMed Inc., a world-leading digital health company, announced results for its quarter ended June 30, 2021.

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial results before the market opens on August 12, 2021.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2021 and provided a corporate update.